RNase is one of several enzymes elaborated by the pancreas. The properties and structure of bovine pancreatic RNase (ribonuclease I; ribonucleate 3'-pyrimidino-oligonucleotidohydrolase; EC 3.1.4.22) have been extensively studied (2). In contrast, information on human pancreatic RNase is meager. Recent studies in this laboratory revealed striking similarities between RNase of hum-an pancreas and that present in human serum (3). Both enzymes have their pH optimum at 6.5 with poly(C) as substrate. Their action on poly(C) is inhibited by poly(A) and poly(G). They are absolutely dependent on phosphate or citrate for their activity. They are thermostable at pH 4.2 and thermolabile at pH 8.5. They are highly specific to secondary phosphate esters of cytidine 3'-phosphates.
level. In the presence of severe renal insufficiency, marked elevation of serum RNase was also observed. Serum RNase, because of its unique specificity, pancreatic origin, and its abnormal elevation ip sera of patients with pancreatic' cancer, serves as a reliable biochemical marker of carcinoma of the pancreas in the preseince of normal renal function.
Carcinoma of the pancreas is difficult to diagnose because the existing methods are either insensitive or limited in applicability. For this reason, diagnosis is almost always too late. History, physical examination, and roentgenographic, endoscopic, echographic, and isotopic scanning techniques are far from accurate. Serum amylase is an unreliable parameter (1) . Although biopsy is possible, such highly invasive testing is extremely limited in its applicability. Pancreatic cancer is fatal within 12 months for 90% of affected patients and constituted 5 .3% of estimated deaths in 1975; Earlier and more reliable diagnosis would allow new approaches to treatment.
RNase is one of several enzymes elaborated by the pancreas. The properties and structure of bovine pancreatic RNase (ribonuclease I; ribonucleate 3'-pyrimidino-oligonucleotidohydrolase; EC 3.1.4.22) have been extensively studied (2) . In contrast, information on human pancreatic RNase is meager. Recent studies in this laboratory revealed striking similarities between RNase of hum-an pancreas and that present in human serum (3) . Both enzymes have their pH optimum at 6.5 with poly(C) as substrate. Their action on poly(C) is inhibited by poly(A) and poly(G). They are absolutely dependent on phosphate or citrate for their activity. They are thermostable at pH 4.2 and thermolabile at pH 8.5. They are highly specific to secondary phosphate esters of cytidine 3'-phosphates.
These biochemical similarities imply that human pancreas is the source of human serum RNase. This conclusion is at variance with earlier studies (4, 5) which suggested that leukocytes are the source of serum RNase. In our studies, the RNase present in leukocytes is highly specific to secondary phosphate esters of uridine 3'-phosphates and has very little activity toward secondary phosphate esters of cytidine 3'-phosphates (6 Patients. The diagnosis of cancer of patients included in this study was proven by biopsy or by autopsy.
Serum. Venous blood, drawn either from volunteer laboratory workers or patients, was allowed to clot at room temperature for 1 hr and centrifuged at 750 X g for 15 min at room temperature. The serum was removed with a capillary pipette and assayed immediately or stored at -20°.
RNase Assay. Because human serum RNase is highly specific to secondary phosphate esters of cytidine 3'-phosphates, its assay with poly(C) as a substrate is more sensitive than with RNA, which is hydrolyzed only partially. Cleavage of poly(C) by serum RNase was followed by the formation of mono-and oligonucleotides, which were separated from partially digested poly(C) fragments by acid precipitation. The concentration of acid-soluble products was measured at 278 rum (3) . Detailed assay procedure is given in the legend to Table 1 Reaction mixtures consisting of 0.05 ml of poly(C) (100 Mg), 0.15 ml of phosphate-borate buffer (0.1 M with respect to phosphate), pH 6.5, and 0.05 ml of serum that had been diluted 200-fold were incubated at 370 for 15 min and then transferred to an ice bath. To each tube was added, with mixing, 0.25 ml of cold 1.2 M HClO4 containing 0.02 M lanthanum nitrate. After 20 min at 00, the precipitates were removed by centrifugation at 12,100 x g for 30 min in the cold. The supernatants were diluted with H20 and their absorbances were measured at 278 nm. Enzyme and substrate blanks were always run side by side. * Probability that miscellaneous cancers = pancreatic cancer. The individual values of normal persons, patients with pancreatitis, patients with pancreatic cancer, and others with varied cancers were plotted as cumulati've percentages of total persons in each group (Fig. 1) . At a threshold RNase value of 250 units/ml of serum, all normal subjects and all patients with pancreatitis are excluded; 90% of the patients with pancreatic cancer are above the threshold level of 250 units, and 90% of all patients with varied cancers are below this level. Significant increases in serum RNase levels of patients who did not have pancreatic cancer -were also observed. Serum RNase activity of four patients with carcinoma of kidney ranged from 545 to 732 units/ml of serum (Table 1) . Their serum creatinine values ranged from 1.4 to 2.3 mg/100 ml of serum. Sera of six patients with renal failure, obtained just before dialysis, were also investigated. Their serum RNase ranged from 1730 to 3500 units/mil of serum and their creatinine values ranged from 9 to 17 mg/100 ml'of serum. Simultaneous serum RNase and creatinine values were also available for 26 patients with pancreatic cancer; while their serum RNase ranged from 99 to 714 units/ml of serum, their serum creatinine values remained normal, 0.6 to 1.4 mg/100 ml of serum (mean + SD, 0.98 4 0.26 mg). It is evident from these results that, in addition to pancreatic cancer, substantial elevations in serum RNase can also occur in renal insufficiency. The increased serum RNase levels observed in patients with kidney cancer could be due to renal insufficiency and, hence, may not be related to cancer. Elevations in serum RNase were also observed in two patients with carcinoma of gall bladder, in two patients with ampullary carcinoma, and in one patient with ovarian carcinoma, all of whom had upper abdominal masses and were jaundiced. These elevations could result from interference with the normal excretion of pancreatic RNase due to obstruction of ducts. DISCUSSION Human serum RNase, because of its unique specificity, pancreatic origin, and its abnormal elevation in sera of 90% of patients with pancreatic cancer, could serve as a biochemical marker in carcinoma of the pancreas. In the presence of serum RNase values above 250 units/ml, intensive clinical scrutiny is imperative to establish the diagnosis of pancreatic cancer. Correlation of elevated pancreatic RNase with early disease as a diagnostic screening tool and as a monitor of therapeutic results is under investigation. Since serum RNase, which is ordinarily excreted by the renal route (Reddi, unpublished data), increases in the presence of renal insufficiency, an interpretation of its elevation due to pancreatic cancer depends on the presence of normal renal function.
The increased RNase in the serum of pancreatic cancer patients might represent an increased enzyme synthesis by the proliferating tumor cells or might be due to the synthesis of a new species of RNase. It has been shown that neoplastically transformed tissues are capable of synthesizing RNase that differs qualitatively and quantitatively from that existing in their normal counterpart tissues (7) . Recently, an oncofetal antigen complex present only in fetal pancreas and in adult pancreatic carcinoma has been reported (8) . However, its nature and properties are not known.
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